Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT01402531 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Hereditary Hemorrhagic Telangiectasia (HHT)

Interventions

DRUG: Submucosal Bevacizumab

Sponsor

University of California, San Diego